首页> 外国专利> Amorphous substance of Idelalisib and preparation method therefor

Amorphous substance of Idelalisib and preparation method therefor

机译:依达拉西卜的无定形物质及其制备方法

摘要

The present invention relates to an amorphous form of Idelalisib and its methods of preparation. Using a Cu-Kα radiation, the X-ray powder diffraction (XRPD) pattern does not contain sharp diffraction peaks at a diffraction angle expressed in degrees 2θ, and the X-ray powder diffraction pattern is shown in FIG. 1. The present invention also provides a preparation method for the amorphous form of Idelalisib. The amorphous form of Idelalisib of the present invention increases the solubility of Idelalisib and improves bioavailability of the drug product. As compared to the existing crystalline forms of Idelalisib, its solubility increases significantly, which improves body's absorption of the drug and makes it more efficacious in the clinical therapeutic treatment of diseases. Under the stress test conditions, the amorphous material can maintain good physical and chemical stabilities. The preparation method of amorphous Idelalisib according to the present invention is simple to operate and easy to implement.
机译:本发明涉及依达拉西德的无定形形式及其制备方法。使用Cu-Kα辐射,X射线粉末衍射(XRPD)图案在以2θ度表示的衍射角处不包含尖锐的衍射峰,并且X射线粉末衍射图案示于图4中。 1 。本发明还提供了伊德拉利昔的无定形形式的制备方法。本发明的艾达拉西布的无定形形式增加了艾达拉西布的溶解度并改善了药物产品的生物利用度。与依达拉西的现有晶体形式相比,其溶解度显着提高,从而改善了人体对药物的吸收,使其在疾病的临床治疗中更加有效。在压力测试条件下,非晶态材料可以保持良好的物理和化学稳定性。根据本发明的无定形艾达拉西布的制备方法,操作简单,易于实施。

著录项

  • 公开/公告号US10370376B2

    专利类型

  • 公开/公告日2019-08-06

    原文格式PDF

  • 申请/专利权人 ALNOVA PHARMACEUTICALS LTD.;

    申请/专利号US201715783207

  • 发明设计人 XINI ZHANG;ZHIGANG XIONG;TAO HU;

    申请日2017-10-13

  • 分类号C07D473/34;A61K31/52;A61P29;A61P35;A61P37;

  • 国家 US

  • 入库时间 2022-08-21 12:14:22

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号